Lobbying firms have continued to hoover up new business from colleges and universities as the White House escalates its war with higher education.

Australian audiences are about to have their trivia skills put to the test with ABC set to premiere “Claire Hooper’s House of Games,” a new quiz show hosted by Australian comedian Claire Hooper.

The deal is expected to close in the second quarter of 2025 pending approval under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions. It is projected the acquisition will ...

Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals (Hengrui Pharma) for the latter’s investigational oral small-molecule ...

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor. In return for the ex-China rights to the drug, dubbed HRS-5346, Merck has ...

40% of Merck & Co., Inc.'s revenues are driven by cancer med Keytruda, which faces patent expiry by 2028, posing a significant risk to future earnings and share price value. The company is ...

Merck licenses the protein, called berahyaluronidase alfa, from Alteogen. Merck has filed a petition with the U.S. Patent and Trademark Office to challenge seven of Halozyme’s patents.

Merck (NYSE:MRK) has reached a licensing agreement worth nearly $2B with the Chinese drugmaker Jiangsu Hengrui Pharmaceuticals to jointly develop and commercialize an experimental heart disease ...

Merck's stock trades at a low valuation as investors worry about Keytruda's looming patent cliff. The company is looking to a new, subcutaneous formulation, which could help sales remain strong ...

Dr. Michael Hooper is vice president and chief academic officer at Sentara Health and a leader in clinical care and academic medicine. With a wealth of experience in pulmonology and critical care ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.